Latest news in cancer
Dostarlimab-gxly receives accelerated approval from the FDA for dMMR advanced solid tumours
August 2021: Dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) was given accelerated approval by the Food and Drug Administration for adult patients with...
Belzutifan has been approved by the FDA for malignancies linked to von Hippel-Lindau disease
August 2021: Belzutifan (Welireg, Merck), a hypoxia-inducible factor inhibitor, has been approved by the Food and Drug Administration for adult patients with...
The FDA has approved the combination of lenvatinib and pembrolizumab for advanced renal cell carcinoma
August 2021: The combination of lenvatinib (Lenvima, Eisai) and pembrolizumab (Keytruda, Merck) has been approved by the Food and Drug Administration for the...
Pembrolizumab has been approved by the FDA for high-risk early-stage triple-negative breast cancer
August 2021: Pembrolizumab (Keytruda, Merck) was approved by the FDA for high-risk, early-stage triple-negative breast cancer (TNBC) as a neoadjuvant treatment...
Pembrolizumab and lenvatinib have been approved by the FDA for advanced endometrial cancer
August 2021: Pembrolizumab (Keytruda, Merck) in combination with lenvatinib (Lenvima, Eisai) has been approved by the Food and Drug Administration for patients...
The FDA has approved belumosudil for the treatment of chronic graft-versus-host disease
August 2021: After failure of at least two prior lines of systemic therapy, the Food and Drug Administration approved belumosudil (Rezurock, Kadmon...
Daratumumab and hyaluronidase-fihj plus pomalidomide and dexamethasone have been approved by the FDA for the treatment of multiple myeloma
August 2021: Daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) have been approved by the Food and Drug Administration in combination...
The FDA has given enfortumab vedotin-ejfv approval for the treatment of locally advanced or metastatic urothelial carcinoma
August 2021: Enfortumab vedotin-ejfv (Padcev, Astellas Pharma US, Inc.), a Nectin-4-directed antibody and microtubule inhibitor combination, has been approved...
FDA has approved asparaginase erwinia chrysanthemi (recombinant) for leukaemia and lymphoma
August 2021: The Food and Drug Administration has approved asparaginase erwinia chrysanthemi (recombinant)-rywn) (Rylaze, Jazz Pharmaceuticals, Inc.) as part...
Avapritinib has been approved by the FDA for advanced systemic mastocytosis
August 2021: The FDA approved avapritinib (AyvakitTM, Blueprint Medicines Corp.) for adult patients with advanced systemic mastocytosis (AdvSM), which includes...
Infigratinib receives accelerated approval from the FDA for metastatic cholangiocarcinoma
August 2021: Infigratinib (Truseltiq, QED Therapeutics, Inc.), a kinase inhibitor, has been granted accelerated approval by the Food and Drug Administration...
Sotorasib receives accelerated approval from the FDA for KRAS G12C mutant NSCLC
August 2021: The FDA granted accelerated approval to sotorasib (LumakrasTM, Amgen, Inc.), a RAS GTPase family inhibitor, for adult patients with KRAS G12C...
Need help? Our team is ready to assist you.
We wish a speedy recovery of your dear and near one.